Hepatic arterial infusion chemotherapy versus sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombus: An updated meta-analysis and systematic review

BACKGROUND: Sorafenib was the first drug approved for advanced hepatocellular carcinoma (HCC). However, it is limited by poor efficacy for HCC with portal vein tumor thrombus (PVTT). Some studies suggested that hepatic artery infusion chemotherapy (HAIC) could provide survival benefits to patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wei, Ouyang, Deliang, Huang, Zhangkan, Che, Xu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911796/
https://www.ncbi.nlm.nih.gov/pubmed/36776344
http://dx.doi.org/10.3389/fonc.2023.1085166

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911796/
https://www.ncbi.nlm.nih.gov/pubmed/36776344
http://dx.doi.org/10.3389/fonc.2023.1085166

Ejemplares similares